Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.62 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123782 | 0.80 | DHODH (0.59) | MTNR1AMTNR1BDHODHELANEKDM4E | |
| SCHEMBL5117220 | 0.79 | MTNR1A (0.57) | MTNR1AMTNR1BDHODHELANEKDM4E | |
| SCHEMBL6791342 | 0.79 | MTNR1A (0.55) | MTNR1AMTNR1BDHODHELANEKDM4E | |
| SCHEMBL6780473 | 0.78 | MTNR1A (0.61) | MTNR1AMTNR1BELANETLR8 | |
| SCHEMBL6789561 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6785926 | 0.77 | MTNR1A (0.65) | MTNR1AMTNR1BTLR8 | |
| SCHEMBL6790804 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6786760 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6783328 | 0.75 | MTNR1A (0.63) | MTNR1AMTNR1BTLR8 | |
| SCHEMBL6786432 | 0.74 | MTNR1A (0.64) | MTNR1AMTNR1BTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737431-B2 | SUCH AS N-(3-(2-METHYLBENZOXAZOL-7-YL)PROPYL)PROPANAMIDE; CIRCADIAN RHYTHM RELATED DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-18 | — | — | US | disclosed |
| US-20030216456-A1 | Benzoxazole derivatives as novel melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216456-A1 | Benzoxazole derivatives as novel melatonergic agents | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885DHODH 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.